


Curriculum Vitae

Name	Ji Hyun Park, MD.PhD.	
Current Position & Affiliation	Assistant professor, Department of Hemato-oncology, Konkuk University Medical Center, Konkuk University School of Medicine	
Country	Republic of Korea	

Educational Background

2002. 3 – 2004. 2	Premedical course College of Medicine Ewha Woman’s University, Seoul, Korea
2004. 3 – 2008. 2	M.D. Graduate magna cum laude College of Medicine Ewha Woman’s University, Seoul, Korea
2005. 7 – 2005. 8	Clerkship as a medical student Karolinska Institute, Sweden World Health Organization, Switzerland Oxford University, England In the program of LG global challenger, sponsored by LG Inc.
2011. 3 – 2013.2	M.S. Graduate School University of Ulsan College of Medicine, Seoul, Korea
2013.3 – 2016.2	Ph.D . Graduate school University of Ulsan College of Medicine, Seoul, Korea

Professional Experience

2008. 3 – 2009.2 Intern
Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
2009. 3 – 2013.2 Resident, Department of Internal Medicine,
Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
2014. 3 – 2017.2 Fellowship
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
2015. 10 – 2015.11 Visiting doctor
INSERM Unit U981, instructed by Andre Fabrice
(Institut National des Sciences et de Recherche
Medicale)
Institut Gustave Roussy, Villejuif, France
2016. 7 – 2016.10 Staff in Hospitalist Task Force Team
Devise and settle a protocol for Asan Medical Center

Write a proposal for hospitalist project under the
Ministry of Health and Welfare Project, which finally
accepted
- 2017.3 – 2020.2 Clinical Assistant professor,
Department of Hemato-oncology,
Konkuk University Medical Center,
Konkuk University School of Medicine
- 2020.3 – Assistant professor,
Department of Hemato-oncology,
Konkuk University Medical Center,
Konkuk University School of Medicine

Professional Organizations

Member, American Society of Clinical Oncology
Member, European Society of Medical Oncology
Member, Korean Society of Medical Oncology
Member, Korean Cancer Study Group
Member, Korean Cancer Association

Main Scientific Publications

- 24 **JH Park**, GL You, MJ Ahn, S-W Kim, MH Hong, J-Y Han, C-Y Ock, J-S Lee, IJ Oh, SY Lee, CH Kim, YJ Min, YH Choi, JS Ryu, SH Park, HK Ahn, BY Shim, KH Lee, SY Lee, J-S Kim, J Yi, SK Choi, H An, JH Kang
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: First report from Korean Cancer Study Group LU19-05
Accepted in JAN-2021, J Cancer Res Clin Oncol.
- 23 **JH Park**, SH Chun, YG Lee, H Chang, KW Lee, HR Kim, SH Shin, HJ An, KE Lee, IG Hwang, MJ Ahn, SB Kim, B Keam
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12
J Cancer Res Clin Oncol. 2020 Dec; 146 (12): 3359-3369, doi: 10.1007/s00432-020-03316-5
- 22 **JH Park**, JH Ahn, JE Kim, C KH Jung, G Gong, HJ Lee, BH Son, SH Ahn, HH Kim, HJ Shin, DH Moon, D Kim, SB Kim
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]
Anticancer Res. 2020 Oct; 40 (10): 5883-5893, doi: 10.21873/anticancer.14608.
- 21 **JH Park**, SF Jonas, G Bataillon, C Criscitello, R Salgado, S Loi, G Viale, HJ Lee, MV Dieci, S-B Kim, A Vincent-Salomon, G Curigliano, F André, S Michiels
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Annals of Oncology 30: 1941-1949, 2019, doi:10.1093/annonc/mdz395

20. **JH Park**, BS Kwon, SJ Park, W Ji, S Yoon, C-M Choi, JC Lee
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
J Cancer Res Clin Oncol. 2019 May 29. Epub ahead
19. **JH Park**, HJ Lee, SB Lee, JH Ahn, JE Kim, KH Jung, G. Gong, B-H Son, S-H Ahn, S-B Kim
Intrinsic prognostic impact of tumor-infiltrating lymphocytes in systemically untreated patients with early stage triple-negative breast cancer
Anticancer Res, 2019 Jun;39 (6):3111-3119
18. BS Kwon, **JH Park**, S Kim, S Park, W Ji, WS Kim, JC Lee, YR Park, CM Choi
Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer
Tumori. 2019 Jun; 105(3):216-224
17. **JH Park**, JS Lee, H Koo, JE Kim, JH Ahn, MH Ryu, SR Park, SK Yoon, JC Lee, YS Hong, SY Kim, KP Kim, CH Yoo, JY Hong, JL Lee, KH Jung, BY Rhyoo, TW Kim
How cancer patients perceive clinical trials (CTs) in the era of CTs: current perception and its difference between common and rare cancers
J Cancer Edu, 2019 Feb, Epub ahead of print
16. **JH Park**, JH Ahn, SB Kim
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
ESMO open, Accepted in 2018. March
15. KM Song, J Lee, **JH Park**, SY Park, TB Kim, C Suh
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
Blood Research. 2018 Mar;53(1):71-74
14. SY Kim, **JH Park**, SY Yoon, YH Cho, MH Lee
A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia
Cancer Chemotherapy Pharmacology. 2018 Feb;81(2):393-398

13. JW Hyun, **JH Park**, BG Kang, JK Kim, SH Kim, KD Park, SH Hwang, HS Gwak, HJ Kim
Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis
Oncotarget. 2017 Jun;8(32):53326-53335
12. **JH Park**, DH Yoon, S.Kim, JS Park, C-S Park, H. Sung, S-W Lee, J.Huh, C Suh
Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphoma (MZL)
Hematologic Oncology. (2018) Feb;36(1):56-61
11. BS Kwon, **JH Park**, WS Kim, JS Song, CM Choi, JK Rho, JC Lee
Predictive factors for switched EGFR-TKIs retreatment in patients with EGFR-mutant Non-small cell lung cancer
Tuberculosis and Respiratory Disease. (2017), Apr;80(2):187-193
10. S. Seo, JY Hong, S. Yoon, C. Yoo, **JH Park**, JB Lee, C-S Park, J. Huh, Y. Lee, KW Kim, J-S Ryu, SJ Kim, WS Kim, DH Yoon, C. Suh
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
Oncotarget (2016), October, doi: 10.18632/oncotarget.12734
9. **JH Park**, MJ Kang, JH Ahn, JE Kim, KH Jung, G. Gong, HJ Lee, B-H Son, S-H Ahn, H-H Lee, HJ Shin, D-H Moon, S-B Kim
Phase II Trial of Neoadjuvant Letrozole and Lapatinib in Asian Postmenopausal Women With Estrogen Receptor (ER) and Human Epidermal Growth Factor Receptor-2 (HER-2) Positive Breast Cancer [Neo-ALL-IN]: Highlighting the TILs, ER Expressional Change after Neoadjuvant Treatment, and FES-PET as Potential Significant Biomarkers
Cancer Chemotherapy and Pharmacology (2016), August, 78:685, doi: 10.1007/s00280-016-3107-6
8. **JH Park**, YJ Choi, SY Kim, J-E Lee, KJ Sung, S.Park, WS Kim, JS Song, C-M Choi, YH Sung, JK Rho, JC Lee
Activation of IGF1R Pathway Potentially Mediates Acquired Resistance to Mutant-selective 3rd-generation EGF Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer
Oncotarget (2016), March, doi: 10.18632/oncotarget.8013

7. **JH Park**, DH Yoon, S.Kim, JS Park, C-S Park, H. Sung, S-W Lee, J.Huh, C Suh
Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma
Annals of Hematology (2016), April, 95: 801-808, doi: 10.1007/s00277-016-2610-5
6. **JH Park**, M-H Ryu, HJ Kim, B-Y Ryoo, C. Yoo, I. Park, YS Park, ST Oh, JH Yook, BS Kim, Y-K Kang
Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer,
Gastric Cancer (2016) Jan; 19 (1): 226-33, doi 10.1007/s10120-015-0464-5
5. **JH Park**, M-H Ryu, YS Park, SR Park, Y-S Na, B-Y Rhoo, Y-K Kang (2015)
Successful control of heavily pretreated metastatic gastric cancer with the mTOR Inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
BMC Cancer, (2015) Mar 13;15:119, doi 10.1186/s12885-015-1139-7
4. **JH Park**, J-L Lee
Intravenous 3-Weekly Paclitaxel and Metronomic Oral Cyclophosphamide in Patients with Advanced Urothelial Cancer Previously Treated with Gemcitabine and Platinum,
Cancer Chemotherapy and Pharmacology (2015): 75 (2), 247-254, doi: 10.1007/s00280-014-2640-4.
3. **JH Park**, DH Yoon, SM Kim, S.Kim, S-W Lee, C-S Park, J.Huh, C Suh
The highest prognostic impact of LDH among International Prognostic Indices (IPI): An explorative study of five IPI factors among patients with DLBCL in the era of Rituximab, *Annals of Hematology* (2014), 93 (10), 1755-1764, doi: 10.1007/s00277-014-2115-z
2. Kang, Y. K., Yoo, C., Ryoo, B. Y., Lee, J. J., Tan, E., **Park JH**, Park, I., et al.
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
British Journal of Cancer (2013), 109(9), 2309–2315. doi:10.1038/bjc.2013.594
1. C Yoo, **JH Park (Co-first author)**, DH Yoon, SI Park, HR Kim, JH Kim, HY Jung, GH Lee, KD Choi, HJ Song, HY Song, JH Shin, KJ Cho, YH Kim, SB Kim
Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients with advanced Esophageal Cancer
Annals of Thoracic Surgery 2012;94(6);1862-1868